What is Immunovant?
Immunovant, Inc. is a biopharmaceutical firm specializing in the development of treatments for autoimmune diseases. The company is a leader in FcRn inhibitor technology, with its investigational compound, batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). This technology aims to address significant unmet patient needs across a range of severe autoimmune conditions, positioning Immunovant at the forefront of therapeutic innovation in this critical medical sector.
How much funding has Immunovant raised?
Immunovant has raised a total of $850M across 3 funding rounds:
Stock Offering
$200M
Corporate Investment
$200M
Share Placement
$450M
Stock Issuance/Offering (2020): $200M, investors not publicly disclosed
Corporate Investment (2021): $200M led by Roivant Sciences
Share Placement (2025): $450M, investors not publicly disclosed
Key Investors in Immunovant
Roivant Sciences
Founded in 2014 and headquartered in London, Roivant Sciences is a tech-enabled healthcare company focused on completing the development of promising late-stage drug candidates and delivering innovative healthcare technologies to patients.
What's next for Immunovant?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for Immunovant. This capital infusion is expected to accelerate the clinical development of batoclimab and potentially other pipeline assets, enabling the company to advance its mission of improving the lives of individuals affected by autoimmune diseases. The company's trajectory suggests a strong focus on scaling operations and advancing its therapeutic candidates through late-stage trials, aiming to bring novel treatments to market.
See full Immunovant company page
